These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33902424)

  • 41. Immunotherapy for Triple-Negative Breast Cancer: Latest Research and Clinical Prospects.
    Ahmed RF; Jameel F; Irfan M
    Crit Rev Immunol; 2019; 39(3):211-221. PubMed ID: 32421965
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunotherapy for metastatic breast cancer.
    Sugie T
    Chin Clin Oncol; 2018 Jun; 7(3):28. PubMed ID: 30056730
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials.
    Hall PE; Schmid P
    Expert Opin Emerg Drugs; 2021 Jun; 26(2):131-147. PubMed ID: 33870839
    [No Abstract]   [Full Text] [Related]  

  • 44. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.
    Brufsky AM; Dickler MN
    Oncologist; 2018 May; 23(5):528-539. PubMed ID: 29352052
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pertuzumab in HER2-positive breast cancer.
    Sendur MA; Aksoy S; Altundag K
    Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Update on current and new potential immunotherapies in breast cancer, from bench to bedside.
    Alaluf E; Shalamov MM; Sonnenblick A
    Front Immunol; 2024; 15():1287824. PubMed ID: 38433837
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC).
    Blackley EF; Loi S
    Breast; 2019 Nov; 48 Suppl 1():S44-S48. PubMed ID: 31839159
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advancements in Human Breast Cancer Targeted Therapy and Immunotherapy.
    Bou-Dargham MJ; Draughon S; Cantrell V; Khamis ZI; Sang QA
    J Cancer; 2021; 12(23):6949-6963. PubMed ID: 34729098
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
    Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
    J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
    [TBL] [Abstract][Full Text] [Related]  

  • 50. First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?
    Fabi A; Malaguti P; Vari S; Cognetti F
    J Exp Clin Cancer Res; 2016 Jun; 35():104. PubMed ID: 27357210
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Breast cancer under age 40: a different approach.
    Ribnikar D; Ribeiro JM; Pinto D; Sousa B; Pinto AC; Gomes E; Moser EC; Cardoso MJ; Cardoso F
    Curr Treat Options Oncol; 2015 Apr; 16(4):16. PubMed ID: 25796377
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emerging immunotherapy strategies in breast cancer.
    Page DB; Naidoo J; McArthur HL
    Immunotherapy; 2014; 6(2):195-209. PubMed ID: 24491092
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Natural and therapy-induced immunosurveillance in breast cancer.
    Kroemer G; Senovilla L; Galluzzi L; André F; Zitvogel L
    Nat Med; 2015 Oct; 21(10):1128-38. PubMed ID: 26444637
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy.
    Yang R; Li Y; Wang H; Qin T; Yin X; Ma X
    Mol Biomed; 2022 Mar; 3(1):8. PubMed ID: 35243562
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Beyond trastuzumab: new treatment options for HER2-positive breast cancer.
    Saini KS; Azim HA; Metzger-Filho O; Loi S; Sotiriou C; de Azambuja E; Piccart M
    Breast; 2011 Oct; 20 Suppl 3():S20-7. PubMed ID: 22015288
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
    Spigel DR; Socinski MA
    J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
    [TBL] [Abstract][Full Text] [Related]  

  • 57. First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial.
    Rimawi M; Ferrero JM; de la Haba-Rodriguez J; Poole C; De Placido S; Osborne CK; Hegg R; Easton V; Wohlfarth C; Arpino G;
    J Clin Oncol; 2018 Oct; 36(28):2826-2835. PubMed ID: 30106636
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Role of clustered HER2/neu amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer].
    Kolyadina IV; Zavalishina LE; Ganshina IP; Andreeva YY; Frank GA; Gordeeva OO; Zhukova LG; Meshcheryakov AA; Savelov NA; Tuzova EA; Morozov DA; Poddubnaya IV
    Arkh Patol; 2019; 81(6):56-62. PubMed ID: 31851193
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview.
    Crucitta S; Cucchiara F; Sciandra F; Cerbioni A; Diodati L; Rafaniello C; Capuano A; Fontana A; Fogli S; Danesi R; Re MD
    Anticancer Agents Med Chem; 2022; 22(4):760-774. PubMed ID: 34348634
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent advances in breast cancer immunotherapy: The promising impact of nanomedicines.
    Hashemzadeh N; Dolatkhah M; Adibkia K; Aghanejad A; Barzegar-Jalali M; Omidi Y; Barar J
    Life Sci; 2021 Apr; 271():119110. PubMed ID: 33513401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.